Registry Of Pregnancy And Cardiac disease (ROPAC)

Download the ROPAC General Presentation and promote ROPAC in your country.

Objectives and characteristics of the study

The impact of pregnancy on women with heart disease or the impact of maternal disease on the outcome of pregnancy for the baby is not yet fully understood. Pregnant women may have a spectrum of structural heart disease including congenital heart disease, rheumatic heart disease, pulmonary hypertension, cardiomyopathy, aortic disease and coronary artery disease. The heterogeneous nature of this group means that the information we use currently to develop our management protocols is incomplete and fragmented. The information provided by this registry will enable us to improve the accuracy of advice to women both before and during pregnancy and to develop better management protocols. It may also allow randomized studies to be targeted at specific problems. Such a registry has to be large in order to collect information on a sufficient numbers of patients with the wide variety of possible situations which may occur.

Objectives

• Determine the variation over the participating countries of structural heart disease for pregnant patients in the participating countries: Assess the maternal and foetal mortality and morbidity during pregnany and 6 months after pregnancy:
  • Type of heart disease (i.e. valvular, congenital, ischaemic, cardiomyopathy)
  • Age during pregnancy
  • Medication used before/during pregnancy
  • Mode of delivery
• Document the incidence of congenital heart disease in the babies born from women with congenital heart disease
• Assess prospectively the changes in maternal cardiac function as a consequence of pregnancy using echocardiography
• Assess use of medical resources utilisation (caesarean section, epidural anaesthesia) and its impact on outcome in different countries
• Assess the results and complication rate of interventions performed during pregnancy
• Test the value of the existing risk models on pregnancy outcome in patients with heart disease
• Compare different types of anticoagulant therapy strategies used during pregnancy

Characteristics

Today more than 60 countries are participating in the registry, and we expect more to join!

If you wish to know more about this registry or to participate please contact us by clicking on the button below:

contact us

If you are already registered as a participant in the EORP programme, you may connect to our secure website: http://www.eorp.org

Study Organisation

ROPAC is conducted in collaboration with the ESC Working Group on Congenital Heart Disease, the ESC Working group on Heart Valve Disease and the Association for European Paediatric and Congenital Cardiology.

The Executive Committee of the registry is chaired by Professor Roger Hall (UK) and Professor Jolien Roos-Hesselink (NL) on behalf of the ESC and EORP.

Executive Committee

Jolien Roos-Hesselink (Co-Chair)
Roger Hall (Co-Chair)
Luigi Tavazzi (Past-Chair EORP Oversight Committee)
Aldo Pietro Maggioni, EORP Scientific Coordinator, ex-officio (non-voting)
Mark Johnson, UK
Jorg Stein, AT
Gary Webb, US
Uri Elkayam, US
Ariane Marelli, CA
Ulf Thilen, SE
Werner Budts, BE
Harald Kaemerer, DE
Karen Sliwa, ZA
William Anthony Parsonage, AU